June 18, 2020 -- Alpine Immune Sciences and AbbVie have entered an exclusive worldwide option and license agreement for ALPN-101, a dual cluster of differentiation 28 (CD28) and inducible T-cell co-stimulator (ICOS) immune antagonist.
CD28 and ICOS are key immune modulators that play roles in multiple autoimmune and inflammatory diseases. ALPN-101 is a potent inhibitor of both CD28 and ICOS pathways as demonstrated in multiple preclinical disease models.
Under the agreement, Alpine will receive an upfront payment of $60 million and will be eligible to receive development, regulatory, and commercial milestone payments of up to $805 million. Alpine will also be eligible for tiered royalties on net sales of ALPN-101. AbbVie will have the option to exclusively license ALPN-101.
Alpine will conduct a phase II clinical study in systemic lupus erythematosus. AbbVie will conduct all future clinical development, manufacturing, and commercialization for ALPN-101.